Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

179.25 -2.82 (-1.55%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

26 27 Next >

AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

September 28, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

Axsome Therapeutics Stock Clears Key Benchmark, Hits 80-Plus RS Rating ↗

September 27, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

Analyst Ratings for Axsome Therapeutics ↗

September 25, 2023

Via Benzinga

Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day

September 21, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

2 Top Biotech Stocks Defying the Bear Market ↗

September 15, 2023

The best may be yet to come for these companies.

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

September 12, 2023

You can get in early on these potential winners.

Via The Motley Fool

Analyst Ratings for Axsome Therapeutics ↗

August 11, 2023

Via Benzinga

Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023

September 07, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics to Present at Three Upcoming Investor Conferences

September 05, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

The Top Healthcare Stocks to Buy With $100 ↗

August 30, 2023

Both stocks have outperformed the broader market in the last 12 months.

Via The Motley Fool

These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy? ↗

August 24, 2023

Today's market loser could be tomorrow's market winner.

Via The Motley Fool

Expert Ratings for Axsome Therapeutics ↗

July 17, 2023

Via Benzinga

Why Shares of Axsome Therapeutics Fell Wednesday ↗

June 28, 2023

The biopharmaceutical company announced a $225 million stock sale.

Via The Motley Fool

Got $200? 3 Growth Stocks to Buy That Could Double Your Money ↗

August 19, 2023

There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good.

Via The Motley Fool

Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

August 15, 2023

A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance.

Via Investor's Business Daily

3 Explosive Stocks to Buy Right Now ↗

August 10, 2023

These stocks are poised to pop in the not-too-distant future.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023 ↗

August 08, 2023

Via Benzinga

DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

August 08, 2023

Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market...

Via Benzinga

FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says ↗

August 07, 2023

Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.

Via Benzinga

Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript ↗

August 07, 2023

AXSM earnings call for the period ending June 30, 2023.

Via The Motley Fool

Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 07, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

3 Fantastic Growth Stocks to Buy in August ↗

August 05, 2023

These stocks could be poised to soar.

Via The Motley Fool

Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond ↗

August 03, 2023

There's lots of upside potential for these drugmakers.

Via The Motley Fool

The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023 ↗

July 20, 2023

These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector.

Via InvestorPlace

Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

July 17, 2023

Keybanc boosted the price target for Camping World Holdings, Inc. (NYSE: CWH) from $28 to $36. Keybanc analyst Noah Zatzkin maintained an Overweight rating. Camping World shares rose 1.4% to $32.04 in...

Via Benzinga

Got $500? 3 Growth Stocks to Buy That Could Double Your Money ↗

July 13, 2023

There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good.

Via The Motley Fool

Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7

July 12, 2023

Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time

From Axsome Therapeutics, Inc.

Via GlobeNewswire

Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults

July 07, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

5 Top Stocks for July ↗

July 01, 2023

This basket of stocks has it all, including growth, dividend income, and value.

Via The Motley Fool

Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock

June 30, 2023

From Axsome Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

26 27 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.